Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LENZ
Strong SellSinkerLENZ Therapeutics, Inc. · Healthcare · United States · $161M · Avg Vol: $4M/d
COMPANY DESCRIPTION
LENZ Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for presbyopia, an age-related loss of near vision. It targets a large, underserved patient population with an innovative, non-surgical solution, aiming to offer a more convenient and effective treatment option. LENZ is a specialty ophthalmology biopharma focused on commercializing a potentially first-in-class product for a widespread vision condition.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 15.0M | 0 | 0 | 19.1M | 8.4% | 21.5M | 17.0M | 43.0M | 50.1% |
| EPS | -0.30 | -0.42 | -2.74 | -2.34 | -2.85 | — | -4.13 | -4.25 | -3.08 | — |
| Shares | 25.5M | 25.5M | 25.5M | 27.5M | 31.3M | +22.8% | 31.4M | — | — | — |
| Debt | 0 | 0.3M | 0.3M | 1.4M | 0.8M | 48.3% | 0.6M | — | — | — |
| Equity | -14.2M | -24.2M | -92.7M | 204.1M | 284.3M | 39.3% | — | — | — | — |
| Op CF | -5.4M | -4.1M | -60.4M | -59.4M | -69.2M | — | -113.9M | — | — | — |
| Inv CF | -9.0K | -37.0K | -29.6M | -154.5M | -75.7M | — | — | — | — | — |
| Fin CF | 22.8M | 30.3M | 80.7M | 199.0M | 149.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LENZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LENZ | LENZ Therapeutics, Inc.(you) | $161M | 14 | Strong Sell |
| OTLK | Outlook Therapeutics, Inc. | $156M | 14 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
| SPRB | Spruce Biosciences, Inc. | $175M | 14 | Strong Sell |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 11 | Strong Sell |
| INDP | Indaptus Therapeutics, Inc. | $152M | 10 | Strong Sell |
| UNCY | Unicycive Therapeutics, Inc. | $144M | 11 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 12 | Strong Sell |
| ABOS | Acumen Pharmaceuticals, Inc. | $211M | 13 | Strong Sell |
| ANIX | Anixa Biosciences, Inc. | $118M | 14 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%